Sang Hoon HanJialun ZhouSuneeta SaghayamSasheela VanarNittaya PhanuphakYi Ming A. ChenThira SirisanthanaSomnuek SungkanuparphChristopher K.C. LeeSanjay PujariPatrick C.K. LiShinichi OkaVonthanak SaphonnFujie ZhangTuti Parwati MeratiMatthew G. LawJun Yong ChoiYonsei University College of MedicineKirby InstituteYR Gaitonde Centre for AIDS Research and EducationUniversity of MalayaThai Red Cross AIDS Research CentreNational Yang-Ming University TaiwanResearch Institute for Health SciencesMahidol UniversityHospital Sungai BulohInstitute of Infectious DiseasesQueen Elizabeth Hospital Hong KongNational Center for Global Health and MedicineNational Center for HIV/AIDSBeijing Ditan HospitalUniversitas Udayana2018-05-032018-05-032011-07-11Endocrine Journal. Vol.58, No.6 (2011), 475-48413484540091889592-s2.0-79959944286https://repository.li.mahidol.ac.th/handle/20.500.14594/11513The prevalence of and risk factors for lipodystrophy (LD) among patients receiving combined antiretroviral treatment (cART) in the Asia-Pacific region are largely unknown. LD diagnosis was based on the adverse event definition from the US NIH Division of AIDS (2004 version), and only cases with a severity grade of ≥ 3 were included. TAHOD patients who had recently commenced cART with ≥ 3 drugs after 1996 from sites which had ever reported LD were included in the analysis. Covariates for the forward multivariate logistic regression model included demographic variables, CDC disease classification, baseline CD4 and viral load, hepatitis B/C virus co-infection, and regimen and duration of cART. LD was diagnosed in 217 (10.5%) of 2072 patients. The median duration of cART was 3.8 (interquartile range, 2.2-5.3) years (stavudine, 2.0 (1.0-3.5) years; zidovudine, 1.8 (0.6-3.9) years; and protease inhibitors (PI), 2.6 (1.3-4.5) years). In the multivariate model, factors independently associated with LD included use of stavudine (≤ 2 years vs. no experience: OR 25.46, p < 0.001, > 2 years vs. no experience: OR 14.92, p < 0.001), use of PI ( > 2.6 years vs. no experience: OR 0.26, p < 0.001), and total duration of cART ( > vs. ≤ 3.8 years: OR 4.84, p < 0.001). The use of stavudine was strongly associated with LD in our cohort. Stavudine-sparing cART strategies are warranted to prevent the occurrence of LD in the Asia-Pacific region. ©The Japan Endocrine Society.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicineArticleSCOPUS10.1507/endocrj.K10E-407